Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 930-690-7
CAS number: -
These data suggest that the registered substance as a whole may be absorbed to some extent following oral and inhalation routes of exposure. Some components within this complex mixture constituting the registered substance may be more absorbed more readily than other components.
No specific ADME and/or toxicokinetic data are available for the
registered substance. Following a single oral administration to rats of
both sexes at the limit dose of 2000 mg/kg no signs of systemic toxicity
were noted. Similarly, following a single dermal application of a
structurally related substance at the limit dose of 2000 mg/kg no signs
of systemic toxicity but only local irritating effects were noted. In
inhalation experiments in which mice were exposed for 2 hours to very
high aerosol concentrations, clinical signs such as reduced activity,
uncoordinated movements together with dyspnoea were noted in animals
before death, however, the LC50 was calculated to be 19 ± 1.4 mg/L, much
higher than the limit dose.
In a developmental toxicity study (Oral Gavage) in the rat (OECD 414)
there was a slight decrease in food consumption and body-weight gain in
all treatment groups. There were effects on embryofetal development in
animals tested in the two highest dose groups of 100 mg/kg/day and 250
mg/kg/day. There were incidents of diaphragmatic hernia recorded in
three fetuses from three litters of animals dosed at 250 mg/kg bw/day.
There were no test-item-related findings upon necropsy.
These data suggest that the registered substance as a whole may be
absorbed to some extent following oral and inhalation routes of
exposure. Some components within this complex mixture constituting the
registered substance may be more absorbed more readily than other
components. Although acute dermal data gives little indicate as to the
absorption through the skin, there will be at least some, because the
substance was able to penetrate to produce skin sensitisation (based on
results of a LLNA study) and animal studies with materials called "shale
oils" in the public domain evidenced a carcinogenic response following
repeated dermal applications to mice and rabbits. Although the
registered substance is irritating for both the skin and eye, these
tumours were not considered related only to local effects.
In the absence of any fully quantitative information, in line with ECHA
guidance inhalation absorption is considered to be 100 % and oral and
dermal absorption are considered to by 50 % for each of these routes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again